KBC Group’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.82M | Buy |
94,767
+89,456
| +1,684% | +$3.34M | 0.01% | 528 |
|
|
2025
Q4 | $185K | Buy |
5,311
+104
| +2% | +$8.17K | ﹤0.01% | 940 |
|
|
2025
Q3 | $433K | Hold |
5,207
| – | – | ﹤0.01% | 725 |
|
|
2025
Q2 | $382K | Buy |
5,207
+1,089
| +26% | +$79K | ﹤0.01% | 730 |
|
|
2025
Q1 | $470K | Hold |
4,118
| – | – | ﹤0.01% | 740 |
|
|
2024
Q4 | $208K | Buy |
4,118
+1,296
| +46% | +$67.9K | ﹤0.01% | 1106 |
|
|
2024
Q3 | $131K | Buy |
2,822
+496
| +21% | +$17.6K | ﹤0.01% | 1121 |
|
|
2024
Q2 | $76K | Hold |
2,326
| – | – | ﹤0.01% | 1341 |
|
|
2024
Q1 | $59K | Hold |
2,326
| – | – | ﹤0.01% | 1451 |
|
|
2023
Q4 | $76K | Sell |
2,326
-285
| -11% | -$7.83K | ﹤0.01% | 1231 |
|
|
2023
Q3 | $71K | Sell |
2,611
-4,496
| -63% | -$130K | ﹤0.01% | 1174 |
|
|
2023
Q2 | $158K | Sell |
7,107
-658
| -8% | -$15.1K | ﹤0.01% | 1014 |
|
|
2023
Q1 | $168K | Sell |
7,765
-715
| -8% | -$15.7K | ﹤0.01% | 1033 |
|
|
2022
Q4 | $172K | Hold |
8,480
| – | – | ﹤0.01% | 1017 |
|
|
2022
Q3 | $217K | Hold |
8,480
| – | – | ﹤0.01% | 943 |
|
|
2022
Q2 | $202K | Sell |
8,480
-1,400
| -14% | -$30.5K | ﹤0.01% | 981 |
|
|
2022
Q1 | $222K | Hold |
9,880
| – | – | ﹤0.01% | 1024 |
|
|
2021
Q4 | $196K | Sell |
9,880
-3,838
| -28% | -$77.9K | ﹤0.01% | 1080 |
|
|
2021
Q3 | $270K | Sell |
13,718
-13,718
| -50% | -$287K | ﹤0.01% | 1016 |
|
|
2021
Q2 | $604K | Hold |
27,436
| – | – | ﹤0.01% | 1017 |
|
|
2021
Q1 | $652K | Hold |
27,436
| – | – | ﹤0.01% | 983 |
|
|
2020
Q4 | $3.95M | Sell |
27,436
-6,856
| -20% | -$144K | ﹤0.01% | 900 |
|
|
2020
Q3 | $597K | Hold |
34,292
| – | – | ﹤0.01% | 896 |
|
|
2020
Q2 | $576K | Buy |
34,292
+17,146
| +100% | +$241K | ﹤0.01% | 941 |
|
|
2020
Q1 | $204K | Sell |
17,146
-31,346
| -65% | -$388K | ﹤0.01% | 1023 |
|
|
2019
Q4 | $587K | Hold |
48,492
| – | – | ﹤0.01% | 1061 |
|
|
2019
Q3 | $685K | Hold |
48,492
| – | – | 0.01% | 999 |
|
|
2019
Q2 | $541K | Hold |
48,492
| – | – | ﹤0.01% | 1046 |
|
|
2019
Q1 | $569K | Buy |
+48,492
| New | +$603K | ﹤0.01% | 1045 |
|
|
2018
Q4 | – | Sell |
-308,474
| Closed | -$4.33M | – | 1325 |
|
|
2018
Q3 | $4.33M | Sell |
308,474
-60,666
| -16% | -$848K | 0.03% | 466 |
|
|
2018
Q2 | $5.8M | Buy |
+369,140
| New | +$6.42M | 0.05% | 379 |
|
|
2014
Q1 | – | Sell |
-6,555
| Closed | -$21K | – | 1303 |
|
|
2013
Q4 | $21K | Hold |
6,555
| – | – | ﹤0.01% | 1289 |
|
|
2013
Q3 | $10K | Hold |
6,555
| – | – | ﹤0.01% | 1241 |
|
|
2013
Q2 | $11K | Buy |
+6,555
| New | +$11.8K | ﹤0.01% | 1222 |
|
Other funds holding CORT
ISL
VPM
VCM
PA
KBC Group's CORT Position: Q1 2026 in Review
KBC Group increased its Corcept Therapeutics (CORT) stake by 1,684% in Q1 2026, buying an estimated $3.34M and bringing the position to 94,767 shares worth $3.82M. The position accounts for 0.01% of the portfolio, ranked #528.
KBC Group first reported a position in CORT in Q2 2013 and has held it in 34 quarters since. The position peaked at $5.8M in Q2 2018. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.
- KBC Group held 94,767 shares of Corcept Therapeutics worth $3.82M as of Q1 2026.
- KBC Group bought 89,456 Corcept Therapeutics shares in Q1 2026, an estimated $3.34M.
- Corcept Therapeutics made up 0.01% of KBC Group's portfolio in Q1 2026, its #528 holding.
- KBC Group first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 34 quarters since.
- KBC Group's Corcept Therapeutics position peaked at $5.8M in Q2 2018.
- 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.
Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.